

Small-cell lung cancer patients face barriers to receiving standard-of-care treatment

January 4 2018

Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of U.S. patients do not receive these treatments and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center.

The findings, reported today in *JAMA Oncology*, also describe obstacles encountered by patients when receiving cancer treatments, such as their insurance status and [socioeconomic factors](#).

"For patients who received both chemotherapy and radiation, median survival was 18 months. Among the group of patients who received neither chemotherapy nor radiation, prognosis was dismal with a median survival of only 3-4 months," explained senior author Stephen G. Chun, M.D., assistant professor of Radiation Oncology. "In order to improve access to care and address related disparities, it is critical to understand the barriers patients face when getting treated for lung cancer," said Chun.

While patients with Federal government insurance (Medicare/Medicaid) were just as likely to receive chemotherapy as those with private insurance, they were significantly less likely to receive [radiation therapy](#). Being uninsured was associated with a lower likelihood of both chemotherapy and radiation administration, explained Chun.

For the retrospective, population-based study, the MD Anderson team used the National Cancer Database (NCDB), a nationwide outcomes registry of the American College of Surgeons, the American Cancer Society and the Commission on Cancer. They identified 70,247 patients diagnosed with non-metastatic, or limited-stage, SCLC and evaluated survival and socioeconomic factors to determine obstacles to cancer [treatment](#) utilization in the United States.

The patients were 55.3 percent female and 44.7 percent male. Initial treatment was 55.5 percent chemotherapy and radiation, 20.5 percent chemotherapy alone, 3.5 percent radiation alone, 20 percent neither chemotherapy nor radiation and 0.5 percent not reported.

Patients who received chemotherapy and radiation had a median survival of 18.2 months. Patients who received either chemotherapy or radiation alone had a median survival of 10.5 and 8.3 months, respectively. Patients who received neither chemotherapy nor radiation therapy had a significantly worse median survival, 3.7 months, compared with all other treatment groups.

Multiple socioeconomic factors were highly associated with overall survival. Treatment at a non-academic center, lack of health insurance and Medicare/Medicaid coverage were also associated with significantly shorter survival.

"There are targeted access programs that provide competitive reimbursement for the administration of chemotherapy, and our findings suggest that these programs have improved chemotherapy access," said Chun. "However, these programs give no financial assistance for radiation therapy, which could in part, explain why patients with Medicare and Medicaid were less likely to receive radiation."

One limitation of the study was a small amount of cases with insufficient

date or follow-up. The NCDB limits data collected to the first course of treatment. It is impossible to know if patients eventually received standard-of-care treatment, according to Chun. Additionally, while [chemotherapy](#) and [radiation](#) are reported, the NCDB does not provide information on whether they were delivered concurrently or sequentially.

"Receiving appropriate, evidence-based therapies for limited-stage SCLC is critical, and our findings underscore the need for [patients](#) to personally advocate for the standard-of-care treatment for their [cancer](#)," said Chun.

Additional research is planned to further define population patterns, specific treatment insufficiencies and the contributing factors to wide-ranging care delivery.

Provided by University of Texas M. D. Anderson Cancer Center

Citation: Small-cell lung cancer patients face barriers to receiving standard-of-care treatment (2018, January 4) retrieved 24 May 2024 from <https://medicalxpress.com/news/2018-01-small-cell-lung-cancer-patients-barriers.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
